Monosialotetrahexosylganglioside in the treatment of chronic oxaliplatin-induced peripheral neurotoxicity: TJMUCH-GI-001, a randomised controlled trial

[1]  O. Bouché,et al.  Long-Term Prevalence of Sensory Chemotherapy-Induced Peripheral Neuropathy for 5 Years after Adjuvant FOLFOX Chemotherapy to Treat Colorectal Cancer: A Multicenter Cross-Sectional Study , 2020, Journal of clinical medicine.

[2]  W. Baumgärtner,et al.  Neurotrophic effects of GM1 ganglioside, NGF, and FGF2 on canine dorsal root ganglia neurons in vitro , 2020, Scientific Reports.

[3]  Fenghua Wang,et al.  Phase III randomized, placebo‐controlled, double‐blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatin‐induced peripheral neurotoxicity in stage II/III colorectal cancer , 2019, Cancer medicine.

[4]  L. V. van de Poll-Franse,et al.  Anxiety and depression mediate the association between chemotherapy‐induced peripheral neuropathy and fatigue: Results from the population‐based PROFILES registry , 2019, Psycho-oncology.

[5]  J. Unger,et al.  The Effects of Ganglioside-Monosialic Acid in Taxane-induced Peripheral Neurotoxicity in Patients with Breast Cancer: A Randomized Trial. , 2019, Journal of the National Cancer Institute.

[6]  U. Hänninen,et al.  Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy , 2019, Acta oncologica.

[7]  Thierry Lecomte,et al.  FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer , 2018, The New England journal of medicine.

[8]  R. Labianca,et al.  The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer? , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  A. Briggs,et al.  3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial , 2018, The Lancet. Oncology.

[10]  R. Labianca,et al.  Duration of Adjuvant Chemotherapy for Stage III Colon Cancer , 2018, The New England journal of medicine.

[11]  L. Yin,et al.  Ganglioside GM1 protects against high altitude cerebral edema in rats by suppressing the oxidative stress and inflammatory response via the PI3K/AKT‐Nrf2 pathway , 2018, Molecular immunology.

[12]  P. Grafe,et al.  Axonal excitability changes and acute symptoms of oxaliplatin treatment: In vivo evidence for slowed sodium channel inactivation , 2017, Clinical Neurophysiology.

[13]  E. Ghigo,et al.  Impaired taste sensation in type 2 diabetic patients without chronic complications: a case–control study , 2018, Journal of Endocrinological Investigation.

[14]  C. Nadal,et al.  Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial , 2017, Neurotherapeutics.

[15]  C. Shapiro,et al.  Predictors of duloxetine response in patients with oxaliplatin‐induced painful chemotherapy‐induced peripheral neuropathy (CIPN): a secondary analysis of randomised controlled trial – CALGB/alliance 170601 , 2017, European journal of cancer care.

[16]  M. Okajima,et al.  Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study , 2016, Drug design, development and therapy.

[17]  N. Staff,et al.  Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance). , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  H. Kuroda,et al.  Effect of duloxetine in Japanese patients with chemotherapy-induced peripheral neuropathy: a pilot randomized trial , 2015, International Journal of Clinical Oncology.

[19]  G. Cavaletti,et al.  Long‐term course of oxaliplatin‐induced polyneuropathy: a prospective 2‐year follow‐up study , 2014, Journal of the peripheral nervous system : JPNS.

[20]  D. Shin,et al.  Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. , 2014, The Lancet. Oncology.

[21]  C. Loprinzi,et al.  Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  D. Shibata,et al.  Oxaliplatin-induced peripheral neuropathy’s effects on health-related quality of life of colorectal cancer survivors , 2013, Supportive Care in Cancer.

[23]  V. Lemmens,et al.  Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  C. Shapiro,et al.  Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. , 2013, JAMA.

[25]  S. Jiao,et al.  Ganglioside-monosialic acid (GM1) prevents oxaliplatin-induced peripheral neurotoxicity in patients with gastrointestinal tumors , 2013, World Journal of Surgical Oncology.

[26]  Cristina Santos,et al.  Clinical pattern and associations of oxaliplatin acute neurotoxicity , 2013, Cancer.

[27]  T. Sugiyama,et al.  Preventive effect of traditional Japanese medicine on neurotoxicity of FOLFOX for metastatic colorectal cancer: a multicenter retrospective study. , 2012, Anticancer research.

[28]  P. Ding,et al.  Neuroprotective effect of neurotropin on chronic oxaliplatin-induced neurotoxicity in stage II and stage III colorectal cancer patients: results from a prospective, randomised, single-centre, pilot clinical trial , 2012, International Journal of Colorectal Disease.

[29]  R. Guo,et al.  The effect of monosialotetrahexosylganglioside (GM1) in prevention of oxaliplatin induced neurotoxicity: a retrospective study. , 2012, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[30]  P. Grafe,et al.  Anticancer drug oxaliplatin induces acute cooling-aggravated neuropathy via sodium channel subtype NaV1.6-resurgent and persistent current , 2012, Proceedings of the National Academy of Sciences.

[31]  Y. Bang,et al.  Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial , 2012, The Lancet.

[32]  Shung-Haur Yang,et al.  Duloxetine improves oxaliplatin-induced neuropathy in patients with colorectal cancer: an open-label pilot study , 2012, Supportive Care in Cancer.

[33]  W. Messersmith,et al.  Oxaliplatin-Induced Neuropathy in Colorectal Cancer , 2011, Journal of oncology.

[34]  Harpreet Wasan,et al.  Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial , 2011, The Lancet. Oncology.

[35]  Pierre Michel,et al.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[36]  M. Friedlander,et al.  Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. , 2011, The oncologist.

[37]  P. Novotny,et al.  Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  H-K Arkenau.  Capecitabine combined with oxaliplatin (CAPOX) in clinical practice: how significant is peripheral neuropathy? , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[39]  J. Sloan,et al.  The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial , 2011, Supportive Care in Cancer.

[40]  M. Fallon,et al.  Capecitabine combined with oxaliplatin (CapOx) in clinical practice: how significant is peripheral neuropathy? , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  J. Schneider,et al.  GM1 ganglioside in Parkinson's disease: Results of a five year open study , 2010, Journal of the Neurological Sciences.

[42]  Christophe Hennequin,et al.  Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  J. Farrar,et al.  Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendations , 2009, PAIN.

[44]  N. Petrelli,et al.  Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  M. Friedlander,et al.  Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  Thomas Gruenberger,et al.  Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial , 2008, The Lancet.

[47]  A. Norman,et al.  Capecitabine and oxaliplatin for advanced esophagogastric cancer. , 2008, The New England journal of medicine.

[48]  J. Kopec,et al.  Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  Jin-Hwang Liu,et al.  Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients. , 2007, The oncologist.

[50]  G. Comi,et al.  Ganglioside treatment in diabetic peripheral neuropathy: A multicenter trial , 1983, Acta diabetologia latina.

[51]  A. Windebank,et al.  Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. , 2006, Neurotoxicology.

[52]  M. R. Fighera,et al.  GM1 ganglioside prevents seizures, Na+,K+-ATPase activity inhibition and oxidative stress induced by glutaric acid and pentylenetetrazole , 2006, Neurobiology of Disease.

[53]  C. Tournigand,et al.  OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  M. Dong.  OPTIMOX1:A Randomized Study of FOLFOX4 or FOLFOX7 with Oxaliplatin in A Stop-and-Go Fashion in Advanced Colorectal Cancer——A GERCOR Study , 2006 .

[55]  J. Grem,et al.  Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage‐gated sodium channels , 2005, British journal of pharmacology.

[56]  T. Hickish,et al.  Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. , 2004, The New England journal of medicine.

[57]  C. Tournigand,et al.  FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  A. Zeleniuch‐Jacquotte,et al.  Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  F. Goldwasser,et al.  Exacerbation of oxaliplatin neurosensory toxicity following surgery. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[60]  R. Labianca,et al.  Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  F. Lévi,et al.  Oxaliplatin: pharmacokinetics and chronopharmacological aspects. , 2000, Clinical pharmacokinetics.

[62]  F. Lévi,et al.  Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  S. Wyrick,et al.  Comparative neurotoxicity of oxaliplatin, ormaplatin, and their biotransformation products utilizing a rat dorsal root ganglia in vitro explant culture model , 1999, Cancer Chemotherapy and Pharmacology.

[64]  J. Schneider,et al.  Parkinson's disease Improved function with GMl ganglioside treatment in a randomized placebo‐controlled study , 1998, Neurology.

[65]  M. Marty,et al.  Pharmacokinetics and safety profile of oxaliplatin. , 1998, Seminars in oncology.

[66]  P. Fernyhough,et al.  Role of Neurotrophins in Diabetic Neuropathy and Treatment with Nerve Growth Factors , 1997, Diabetes.

[67]  J. Robert,et al.  Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[68]  J. Schneider,et al.  GM1 ganglioside treatment of Parkinson's disease , 1995, Neurology.

[69]  G. Pozza,et al.  Clinical Uses of Gangliosides in Diabetic Neuropathy , 1993, Diabetic medicine : a journal of the British Diabetic Association.

[70]  V. Wynn,et al.  A double blind placebo controlled trial of mixed gangliosides in diabetic peripheral and autonomic neuropathy. , 1984, Advances in experimental medicine and biology.